Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis by Christopher W. Pohlmeyer, Ching Shang, Pei Han, Zhi-Hua Cui, Randall M. Jones, Astrid S. Clarke, Bernard P. Murray, David A. Lopez, David W. Newstrom, M. David Inzunza, Franziska G. Matzkies, Kevin S. Currie, Julie A. Di Paolo

Get full text